摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes coronavirus disease 2019 (COVID-19), infects humans through a strong interaction between the viral spike protein (S-protein) and angiotensin converting enzyme 2 (ACE2) receptors on the cell surface. The infection of host lung cells by SARS-CoV-2 leads to clinical symptoms in patients. However, ACE2 expression is not restricted to the lungs; altered receptors have been found in the nasal and oral mucosa, vessel, brain, pancreas, gastrointestinal tract, kidney, and heart. The future of COVID-19 is uncertain, however, new viral variants are likely to emerge. The SARS-CoV-2 Omicron variant has a total of 50 gene mutations compared with the original virus; 15 of which occur in the receptor binding domain (RBD). The RBD of the viral S-protein binds to the human ACE2 receptor for viral entry. Mutations of the ACE2-RBD interface enhance tight binding by increasing hydrogen bond interactions and expanding the accessible surface area. Extracorporeal membrane oxygenation, hyperbaric oxygen, and aggressive dialysis for the treatment of COVID-19 have shown various degrees of clinical success. The use of decoy receptors based on the ACE2 receptor as a broadly potent neutralizer of SARS-CoV-2 variants has potential as a therapeutic mechanism. Drugs such as 3E8 could block binding of the S1-subunit to ACE2 and restrict the infection of ACE2-expressing cells by a variety of coronaviruses. Here, we discuss the development of ACE2-targeted strategies for the treatment and prevention of COVID-19.
学科与关键词
- Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 InfectionLu, Mengjia; Yao, Weitong; Li, Yujun*; Ma, Danting; Zhang, Zhaoyong; Wang, Haimin; Tang, Xiaojuan; Wang, Yanqun; Li, Chao; Cheng, Dechun; Lin, Hua; Yin, Yandong*; Zhao, Jincun*; Zhong, Guocai*Microbiology Spectrum, 2023, 11(4).
- Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivoZhang, Zhaoyong; Zeng, Eric; Zhang, Lu; Wang, Weiming; Jin, Yingkang; Sun, Jiye; Huang, Shuxiang; Yin, Wenguang; Dai, Jun; Zhuang, Zhen; Chen, Zhao; Sun, Jing; Zhu, Airu; Li, Fang; Cao, Weitao; Li, Xiaobo; Shi, Yongxia; Gan, Mian; Zhang, Shengnan; Wei, Peilan; Huang, Jicheng; Zhong, Nanshan; Zhong, Guocai*; Zhao, Jingxian*; Wang, Yanqun*; Shao, Weihui*; Zhao, Jincun*Cell Discovery, 2021, 7(1): 65.被引 40
- Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2Han, Pengcheng; Li, Linjie; Liu, Sheng; Wang, Qisheng; Zhang, Di; Xu, Zepeng; Han, Pu; Li, Xiaomei; Peng, Qi; Su, Chao; Huang, Baihan; Li, Dedong; Zhang, Rong; Tian, Mingxiong; Fu, Lutang; Gao, Yuanzhu; Zhao, Xin; Liu, Kefang; Qi, Jianxun*; Gao, George F.*; Wang, Peiyi*Cell, 2022, 185(4): 630-+.被引 260
